Research findings differentiate prostate cancer tumors into five different types
the ONA take:
Determining the appropriate course of treatment for prostate cancer can be a challenge for clinicians.
The disease can be slow growing and never cause a problem for a man or it can be an aggressive disease requiring immediate treatment.
Scientists at Cancer Research UK recently found that prostate cancer has five distinct types, and they also found a way to determine which type of tumor a patient has.
The researchers looked for abnormal chromosomes and measured the activity of 100 genes linked to prostate cancer in healthy and cancerous tissue samples from more than 250 men. They were able to group the tumors into five different types, each with its own genetic fingerprint.
The next step is to confirm their findings in larger studies that further explore how each specific type behaves.
However, the researchers report that their findings could lead to better understanding of the disease and more effective treatment for patients who have aggressive disease.
Prostate cancer has five distinct types, with different ways to determine which type of tumor a patient has.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|